These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34530132)

  • 1. Which LABA/LAMA should be chosen in COPD patients in real life?
    Sposato B; Petrucci E; Serafini A; Lena F; Lacerenza LG; Montagnani A; Alessandri M; Cresti A; Scala R; Rogliani P; Ricci A; Perrella A; Scalese M
    Pulm Pharmacol Ther; 2021 Dec; 71():102076. PubMed ID: 34530132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β
    Weng CF; Wu CC; Wu MH; Lin FJ
    Chest; 2023 Apr; 163(4):799-814. PubMed ID: 36442662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
    Plate T; Friedrich FW; Beier J
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1335-1347. PubMed ID: 32606643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
    Rhee CK; Yoshisue H; Lad R
    Adv Ther; 2019 Mar; 36(3):495-519. PubMed ID: 30742242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
    J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
    J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
    Hsieh MJ; Chen NH; Cheng SL; Tao CW; Wei YF; Wu YK; Chan MC; Liu SF; Hsu WH; Yang TM; Lin MS; Liu CL; Kuo PH; Tsai YH
    Int J Chron Obstruct Pulmon Dis; 2022; 17():967-976. PubMed ID: 35510163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
    Feldman WB; Avorn J; Kesselheim AS; Gagne JJ
    JAMA Intern Med; 2023 Jul; 183(7):685-695. PubMed ID: 37213116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.
    Banerji D; Mahler DA; Hanania NA
    Expert Rev Respir Med; 2016 Jul; 10(7):767-80. PubMed ID: 27223863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.
    Gong Y; Sui Z; Lv Y; Zheng Q; Li L
    Eur J Clin Pharmacol; 2023 Oct; 79(10):1321-1332. PubMed ID: 37507595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
    Muraki M; Kunita Y; Shirahase K; Yamazaki R; Hanada S; Sawaguchi H; Tohda Y
    BMC Pulm Med; 2021 Jan; 21(1):26. PubMed ID: 33441146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS.
    Buhl R; Dreher M; Mattiucci-Guehlke M; Emerson-Stadler R; Eckhardt S; Taube C; Vogelmeier CF
    Adv Ther; 2023 Jul; 40(7):3263-3278. PubMed ID: 37256536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD.
    Gong Y; Lv Y; Liu H; Zheng Q; Li L
    Ther Adv Respir Dis; 2022; 16():17534666211066068. PubMed ID: 35001708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.
    Rogliani P; Matera MG; Ritondo BL; De Guido I; Puxeddu E; Cazzola M; Calzetta L
    Pulm Pharmacol Ther; 2019 Dec; 59():101841. PubMed ID: 31520718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β
    Requena G; Banks V; Czira A; Wood R; Tritton T; Wild R; Compton C; Duarte M; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1781-1795. PubMed ID: 35983168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on LAMA/LABA combinations for COPD.
    Drug Ther Bull; 2017 Jan; 55(1):2-5. PubMed ID: 28057707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis.
    Aziz MIA; Tan LE; Wu DB; Pearce F; Chua GSW; Lin L; Tan PT; Ng K
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3203-3231. PubMed ID: 30349228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.